US House Votes on Protection for Biologic Drugs

According to this article in Pharma Times the US House Panel is voted 47-11 in favor of the 12 year exclusivity amendment that protects branded biologic drugs from generic competition. President Obama, which supported the 7 year exclusive plan, commented that this will keep important drugs off the market and also drive up those costs further.

Billy Tauzin, CEO of PhRMA, and Jim Greenwood, CEO of BIO, are some of the pharma representatives that agree with the House decision. Others like the Generic Pharmaceutical Association are “sincerely disappointed that some members of the House Energy and Commerce Committee have decided to put brand pharmaceutical profits before patient needs.” This will be an up and down battle between both parties for quite some time still.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |